Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312071427> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4312071427 endingPage "43" @default.
- W4312071427 startingPage "39" @default.
- W4312071427 abstract "Nebulized hypertonic saline (HS) improves quality of life and reduces exacerbations in patients with cystic fibrosis. It is unknown if it would offer the same benefits in other hypersecretory pathologies.Retrospective observational study. Patients who passed the tolerance test and started HS 5,8% with one year of follow-up were included. Clinical and healthcare parameters were quantified in the year before and after the start of treatment.101 patients, 60.4% women, 65 years (95% CI 62.4–67.9). 82 (81.2%) bronchiectasis, 6 (5.9%) COPD, 2 (2%) asthma, 1 (1%) ILD, and 10 (9.9%) other causes. There was a reduction in bronchorrhea (91.1% vs 75.2%), recurrent infections (57.4% vs 22.8%) and cycles of antibiotic therapy (1.54 vs 0.55), as well as as an increase in FEV1 (1881 ml vs. 1942 ml) and a decrease in visits to primary care (2.94 vs. 1.1), emergencies (0.36 vs. 0.17) and hospitalizations (0.17 vs. 0.17). 06). 73 patients (72.3%) presented an adequate tolerance.Nebulization of HS 5,8% in patients with bronchial hypersecretion is safe and has a remarkable clinical and healthcare impact.El suero salino hipertónico (SSH) nebulizado mejora la calidad de vida y reduce las exacerbaciones en pacientes con fibrosis quística. Se desconoce si ofrecería los mismos beneficios en otras patologías hipersecretoras.Estudio observacional retrospectivo. Se incluyeron pacientes que superaron la prueba de tolerancia e iniciaron SSH 5,8% con un año de seguimiento. Se cuantificaron parámetros clínicos y asistenciales en los años previo y posterior al inicio del tratamiento.101 pacientes, 60,4% mujeres, 65 años (IC95% 62,4-67,9). 82 (81,2%) bronquiectasias, 6 (5,9%) EPOC, 2 (2%) asma, 1 (1%) EPID y 10 (9,9%) otros. Se evidenció una reducción de la broncorrea (91,1% vs 75,2%), las infecciones de repetición (57,4% vs 22,8%) y los ciclos de antibioterapia (1,54 vs 0,55), así como un aumento del FEV1 (1881 ml vs 1942 ml) y una disminución de las asistencias a atención primaria (2,94 vs 1,1), urgencias (0,36 vs 0,17) y hospitalizaciones (0,17 vs 0,06). 73 pacientes (72,3%) presentaron una adecuada tolerancia.La nebulización de SSH 5,8% en pacientes con hipersecreción bronquial es segura y tiene un destacable impacto clínico y asistencial." @default.
- W4312071427 created "2023-01-04" @default.
- W4312071427 creator A5007114656 @default.
- W4312071427 creator A5025989044 @default.
- W4312071427 creator A5069795974 @default.
- W4312071427 date "2023-01-01" @default.
- W4312071427 modified "2023-10-07" @default.
- W4312071427 title "Medical attention in bilingual territories" @default.
- W4312071427 cites W1963996662 @default.
- W4312071427 cites W2008331479 @default.
- W4312071427 cites W2042667517 @default.
- W4312071427 cites W2044991261 @default.
- W4312071427 cites W2062758047 @default.
- W4312071427 cites W2107540415 @default.
- W4312071427 cites W2122304193 @default.
- W4312071427 cites W2134227642 @default.
- W4312071427 cites W2154563310 @default.
- W4312071427 cites W2171330997 @default.
- W4312071427 cites W2176692378 @default.
- W4312071427 cites W2327031299 @default.
- W4312071427 cites W2780685584 @default.
- W4312071427 cites W2792493605 @default.
- W4312071427 cites W2796501168 @default.
- W4312071427 cites W2916484439 @default.
- W4312071427 cites W3004209803 @default.
- W4312071427 cites W3156439785 @default.
- W4312071427 cites W4249624378 @default.
- W4312071427 cites W4297939067 @default.
- W4312071427 doi "https://doi.org/10.1016/j.medcle.2022.07.021" @default.
- W4312071427 hasPublicationYear "2023" @default.
- W4312071427 type Work @default.
- W4312071427 citedByCount "0" @default.
- W4312071427 crossrefType "journal-article" @default.
- W4312071427 hasAuthorship W4312071427A5007114656 @default.
- W4312071427 hasAuthorship W4312071427A5025989044 @default.
- W4312071427 hasAuthorship W4312071427A5069795974 @default.
- W4312071427 hasConcept C126322002 @default.
- W4312071427 hasConcept C167135981 @default.
- W4312071427 hasConcept C23131810 @default.
- W4312071427 hasConcept C2776042228 @default.
- W4312071427 hasConcept C2776780178 @default.
- W4312071427 hasConcept C2777714996 @default.
- W4312071427 hasConcept C2779379686 @default.
- W4312071427 hasConcept C3017567848 @default.
- W4312071427 hasConcept C71924100 @default.
- W4312071427 hasConceptScore W4312071427C126322002 @default.
- W4312071427 hasConceptScore W4312071427C167135981 @default.
- W4312071427 hasConceptScore W4312071427C23131810 @default.
- W4312071427 hasConceptScore W4312071427C2776042228 @default.
- W4312071427 hasConceptScore W4312071427C2776780178 @default.
- W4312071427 hasConceptScore W4312071427C2777714996 @default.
- W4312071427 hasConceptScore W4312071427C2779379686 @default.
- W4312071427 hasConceptScore W4312071427C3017567848 @default.
- W4312071427 hasConceptScore W4312071427C71924100 @default.
- W4312071427 hasIssue "1" @default.
- W4312071427 hasLocation W43120714271 @default.
- W4312071427 hasOpenAccess W4312071427 @default.
- W4312071427 hasPrimaryLocation W43120714271 @default.
- W4312071427 hasRelatedWork W1957770986 @default.
- W4312071427 hasRelatedWork W2011612780 @default.
- W4312071427 hasRelatedWork W2462739481 @default.
- W4312071427 hasRelatedWork W2469072756 @default.
- W4312071427 hasRelatedWork W2565093911 @default.
- W4312071427 hasRelatedWork W2607106327 @default.
- W4312071427 hasRelatedWork W2613303203 @default.
- W4312071427 hasRelatedWork W2781208394 @default.
- W4312071427 hasRelatedWork W2893912166 @default.
- W4312071427 hasRelatedWork W2912210870 @default.
- W4312071427 hasVolume "160" @default.
- W4312071427 isParatext "false" @default.
- W4312071427 isRetracted "false" @default.
- W4312071427 workType "article" @default.